Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia

Yudivaniel Zihono, Hany Yusmaini, Uswatun Hasanah, Erna Harfiani, Md Ikhsan Mokoagow, Dicky Budiman
{"title":"Metformin Effectiveness in Reducing Mortality among Covid-19 Patients with Type 2 Diabetes Mellitus at a Tertiary Hospital in Indonesia","authors":"Yudivaniel Zihono, Hany Yusmaini, Uswatun Hasanah, Erna Harfiani, Md Ikhsan Mokoagow, Dicky Budiman","doi":"10.20473/fmi.v59i3.46944","DOIUrl":null,"url":null,"abstract":"Highlights: 1. As there is a scarcity of publications on the use of metformin for COVID-19 in Indonesia, the findings of this present study may contribute more insight to the existing body of research and provide data specific to the Southeast Asian population.2. This study revealed a decreased mortality rate associated with metformin use in diabetic patients with mild to moderate COVID-19 infection.3. This study suggests that diabetic patients may continue metformin treatment during a COVID-19 infection as the medication has sustained therapeutic effects.   Abstract COVID-19 patients with comorbidities, such as type 2 diabetes (T2DM), have a higher mortality rate compared to those without any comorbidities. T2DM patients usually receive metformin as their first-line treatment. However, the effectiveness of metformin in reducing mortality rates still requires further analysis. The objective of this study was to analyze the effectiveness of metformin in reducing mortality rates among COVID-19 patients with T2DM. An analytic observational design with a retrospective cohort approach was used in this study. Samples were acquired from hospitalized COVID-19 patients with T2DM medical records at Fatmawati Central General Hospital, Jakarta, Indonesia, throughout 2020–2021. The samples were collected using a purposive sampling technique and analyzed using Chi-square test (p<0.05; RR<1). This study comprised 137 samples, with 56 samples receiving metformin and 81 not receiving metformin. The mortality rate in the sample group that received metformin was lower (19.6%) compared to the group that was not given the medication (38.3%). The Chi-square test results indicated a statistically significant relationship between metformin treatment and a lower mortality rate among COVID-19-contracted individuals with T2DM (p=0.020; RR=0.513). Therefore, this study concludes that the administration of metformin treatment reduces mortality among COVID-19 patients with T2DM.","PeriodicalId":32666,"journal":{"name":"Folia Medica Indonesiana","volume":"24 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Folia Medica Indonesiana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20473/fmi.v59i3.46944","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Highlights: 1. As there is a scarcity of publications on the use of metformin for COVID-19 in Indonesia, the findings of this present study may contribute more insight to the existing body of research and provide data specific to the Southeast Asian population.2. This study revealed a decreased mortality rate associated with metformin use in diabetic patients with mild to moderate COVID-19 infection.3. This study suggests that diabetic patients may continue metformin treatment during a COVID-19 infection as the medication has sustained therapeutic effects.   Abstract COVID-19 patients with comorbidities, such as type 2 diabetes (T2DM), have a higher mortality rate compared to those without any comorbidities. T2DM patients usually receive metformin as their first-line treatment. However, the effectiveness of metformin in reducing mortality rates still requires further analysis. The objective of this study was to analyze the effectiveness of metformin in reducing mortality rates among COVID-19 patients with T2DM. An analytic observational design with a retrospective cohort approach was used in this study. Samples were acquired from hospitalized COVID-19 patients with T2DM medical records at Fatmawati Central General Hospital, Jakarta, Indonesia, throughout 2020–2021. The samples were collected using a purposive sampling technique and analyzed using Chi-square test (p<0.05; RR<1). This study comprised 137 samples, with 56 samples receiving metformin and 81 not receiving metformin. The mortality rate in the sample group that received metformin was lower (19.6%) compared to the group that was not given the medication (38.3%). The Chi-square test results indicated a statistically significant relationship between metformin treatment and a lower mortality rate among COVID-19-contracted individuals with T2DM (p=0.020; RR=0.513). Therefore, this study concludes that the administration of metformin treatment reduces mortality among COVID-19 patients with T2DM.
二甲双胍在降低印度尼西亚一家三甲医院 Covid-19 型 2 型糖尿病患者死亡率方面的效果
亮点1.2. 本研究显示,轻度至中度 COVID-19 感染的糖尿病患者使用二甲双胍可降低死亡率。 3. 本研究表明,糖尿病患者在感染 COVID-19 期间可继续使用二甲双胍治疗,因为该药物具有持续的治疗效果。 摘要 COVID-19 患者如患有 2 型糖尿病(T2DM)等合并症,其死亡率高于无合并症的患者。T2DM 患者通常接受二甲双胍作为一线治疗。然而,二甲双胍在降低死亡率方面的效果仍需进一步分析。本研究旨在分析二甲双胍在降低 COVID-19 T2DM 患者死亡率方面的有效性。本研究采用了回顾性队列分析观察设计。样本来自印度尼西亚雅加达法特玛瓦蒂中央综合医院(Fatmawati Central General Hospital)2020-2021年间的住院COVID-19 T2DM患者病历。样本采用目的性抽样技术收集,并使用卡方检验进行分析(P<0.05;RR<1)。该研究包括 137 个样本,其中 56 个样本接受二甲双胍治疗,81 个样本未接受二甲双胍治疗。与未服用二甲双胍的样本组(38.3%)相比,服用二甲双胍的样本组死亡率较低(19.6%)。卡方检验结果表明,在 COVID-19 签约的 T2DM 患者中,二甲双胍治疗与较低的死亡率之间存在显著的统计学关系(P=0.020;RR=0.513)。因此,本研究得出结论,服用二甲双胍可降低 COVID-19 T2DM 患者的死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
45
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信